Login / Signup

Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.

Yunan LiMingying ZhangMengyao ShengPeng ZhangZizhen ChenWen XingJie BaiTao ChengFeng-Chun YangYuan Zhou
Published in: Journal of cancer research and clinical oncology (2018)
In summary, our findings suggest that targeting KDM6B with GSK-J4 has a therapeutic potential for the treatment of AML.
Keyphrases
  • acute myeloid leukemia
  • signaling pathway
  • pi k akt
  • allogeneic hematopoietic stem cell transplantation
  • drug delivery